Navigation Links
Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
Date:1/16/2008

AURORA, ON, Jan. 16 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX: HBP/Frankfurt: WKN 918846) announced today that it has signed an agreement with KBI Biopharma Inc. ("KBI") to develop a process for preparing L-DOS47 in a lyophilized (freeze-dried powder) vial format suitable for clinical testing.

"This new arrangement advances the Company closer to its objective of initiating clinical testing with L-DOS47," said John Docherty, Helix's president. "The lyophilized packaging format will provide for optimum stability of L-DOS47 while in storage so that individual vials may be reconstituted in liquid form immediately prior to patient administration."

About L-DOS47

L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a highly specific single domain antibody to form a potential new targeted drug product for the treatment of adenocarcinoma of the lung, the most common form of cancer in the world today. L-DOS47 is thought to function by leveraging a natural process in the body called the urea cycle to produce an anti-cancer effect. It is based upon a naturally occurring enzyme called urease that essentially reverses the urea cycle by breaking down urea into metabolites that include ammonia and hydroxyl ions. By doing so at the site of cancerous tissues in the body, L-DOS47 is believed to modify the microenvironmental conditions of lung cancer cells in a manner that leads to their death. Among these theorized effects, L-DOS47 is believed to stimulate an increase in the pH of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra-cellular conditions that are known to be necessary for cancer cell survival. As well, the local production of ammonia at the site of cancerous tissues is thought to readily diffuse into the cancer cells to exert a potent cytotoxic effect by interfering with their critical metabolic functions. Helix intends to seek approval in 2008 by the U.S. Food and Drug Administr
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has ... and secured Otter Capital as a significant new partner. ... of GGI’s Agriplier™ technology, building on recent compelling field ... our first meeting, we have been impressed with Otter ... said Alan Sobba, President and CEO of GGI. “We ...
(Date:8/27/2014)... survive impact by the huge amounts of energy ... energy for photosynthesis. The hypothesis is that the ... the energy throughout the entire protein molecule through ... now managed to successfully ,film, this process. , ... which play a role in photosynthesis and thus ...
(Date:8/27/2014)... , Aug. 27, 2014  A novel ... to help physicians better identify early-stage disease, when ... disability, according to a new study in The ... Diagnostics (NYSE: DGX ) and other ... 14-3-3eta protein outperformed conventional antibody-serum testing, including rheumatoid ...
(Date:8/27/2014)... DUBLIN , Aug. 27, 2014 ... the "Global Enzyme for Pulp & Paper Industry ... The Global Enzyme for Pulp & Paper Industry ... the current state of the global enzyme for pulp ... basic overview of the industry including definitions, classifications, applications ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3DTU researchers film protein quake for the first time 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Global Enzyme for Pulp & Paper Industry Report 2014 2
... Inc.,(OTC Bulletin Board: NGNM) announced today that it plans ... July 31, 2008., The Company has scheduled ... results on July 31, 2008, at 11:00 AM EDT. ... 689-8033 (international) at least,five minutes prior to the call. ...
... James C. Powell, former,President and Chief Operating Officer ... of Nerites Corporation., Under Powell,s guidance, SurModics ... partnerships to commercialize products.,Powell joined SurModics in 1987 ... lead the company,s transition from a diagnostics kit,manufacturer ...
... VEGAS, July 29 American Pacific,Corporation (Nasdaq: APFC ... third quarter financial results on Tuesday, August 5, 2008. ... to participate in,a teleconference to review the financial results ... held Tuesday, August 5, 2008 at 1:30 p.m.,PDT. To ...
Cached Biology Technology:NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008 2James C. Powell Joins Nerites Board of Directors 2American Pacific to Release Financial Results and Hold Fiscal 2008 Third Quarter Investor Teleconference 2
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Society of Human Genetics from October 18 22, ... meant to promote the entry of students, post doctorates ... the basic science community and to encourage the participation ... Genetics. This year MARC conferred 16 awards totaling ...
(Date:8/28/2014)... have identified the developmental on-off switch for Streptomyces ... than two-thirds of the world,s naturally derived antibiotic medicines. ... whether it is possible to manipulate this switch to ... study, appearing August 28 in Cell , found ... cyclic-di-GMP and a larger protein called BldD ultimately controls ...
(Date:8/28/2014)... measuring and imaging how quickly blood flows in the ... drug abuse affects the brain, which may aid in ... better treatment options for recovering drug addicts. The new ... Brook University in New York, USA and the U.S. ... Optical Society,s (OSA) open-access journal Biomedical Optics ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3
... 3 fatty acids in fish oils have been well documented ... and reducing methane emissions. These last two benefits may ... the environment, as methane given off by farm animals is ... March) researchers from University College Dublin reported that by including ...
... years because of an inherited cardiac arrhythmia syndrome ... thanks to a discovery made by Vanderbilt University Medical ... M.D., Ph.D., report this week in Nature Medicine ... lethal arrhythmias in patients with a specific type of ...
... study,s findings appear to echo the insect worlds portrayed in ... characters live in rigidly conformist societies. Scientists from the ... a mathematical model to study the manner in which cooperative ... study identifies that there are two scenarios in which a ...
Cached Biology News:Targeted drug therapy prevents exercise-induced arrhythmias 2Targeted drug therapy prevents exercise-induced arrhythmias 3
... Membrane Protein 2, Synaptobrevin 2). ... homology with any other known ... expected that the antibody will ... multata and bovine due to ...
... encodes two unrelated proteins both of which ... cell cycle in a p53-dependent manner. p14^ARF^ ... degradation of mdm2 proteinrequired for mdm2 modification ... This interaction is mediated by the exon ...
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
...
Biology Products: